dna mosaic env
Vaccineexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 22, 2013 (NCT01970449)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Human immunodeficiency virusImmunity, active
Human immunodeficiency virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- dna mosaic env
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02296541 | Phase 1 | Dec 1, 2014 | Duke University, Harvard University, HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), University of Lausanne |
| NCT01970449 | Phase 1 | Oct 22, 2013 | Center for HIV/AIDS Vaccine Immunology, Harvard University, HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), University of Lausanne |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Harvard University | Academic/Hospital | 2 | 0 | 1 | 2013 |
| HIV Vaccine Trials Network | Academic/Hospital | 2 | 0 | 1 | 2013 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 1 | 2013 |
| University of Lausanne | Academic/Hospital | 2 | 0 | 1 | 2013 |
| Center for HIV/AIDS Vaccine Immunology | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2014 |
6 organizations
Page 1 / 1